Elevated acute phase proteins affect pharmacokinetics in COVID‐19 trials: Lessons from the CounterCOVID ‐ imatinib study

This study aimed to determine whether published pharmacokinetic (PK) models can adequately predict the PK profile of imatinib in a new indication, such as coronavirus disease 2019 (COVID‐19). Total (bound + unbound) and unbound imatinib plasma concentrations obtained from 134 patients with COVID‐19...

Descripción completa

Detalles Bibliográficos
Autores principales: Bartelink, Imke H., Bet, Pierre M., Widmer, Nicolas, Guidi, Monia, Duijvelaar, Erik, Grob, Bram, Honeywell, Richard, Evelo, Amanda, Tielbeek, Ivo P. E., Snape, Sue D., Hamer, Henrike, Decosterd, Laurent A., Jan Bogaard, Harm, Aman, Jurjan, Swart, Eleonora L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646516/
https://www.ncbi.nlm.nih.gov/pubmed/34608769
http://dx.doi.org/10.1002/psp4.12718

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646516/
https://www.ncbi.nlm.nih.gov/pubmed/34608769
http://dx.doi.org/10.1002/psp4.12718

Ejemplares similares